At a time when advances in technology and our hectic pace of life drive us to consume at breakneck speeds, it's important to take time to reflect, read and "breathe in" a part of our past, to recognize the value of the people and principles that they upheld and still now uphold.
To understand the "secrets" that lie behind the growth and have strengthened the Zambon group over the years, it is necessary not only to go back over the company's industrial and financial history but also to investigate the individual and collective values associated with them.
Zambon's history is made up not just of facts and figures but above all of one hundred years of a family history that is inextricably linked with its business to become one single entity.
On 11 November, Gaetano Zambon opens the "Zambon Medicinal Warehouse" in Vicenza along with Silvio Farina.
The company is named “Gaetano Zambon e C”.
The company begins manufacture of Zambon galenic medicines.
The company adopts the brand name “Zef”, taken from the names of the two partners: Gaetano Zambon and Silvio Farina.
Alongside the production of drugs, it also starts synthesizing raw materials.
The first Zambon research laboratory opens in Vicenza.
On 14 May, the Zambon plant is razed to the ground during the American bombing of Vicenza.
The Zambon plant in Vicenza is rebuilt following its destruction. There are 550 employees.
Alberto Zambon, 24 years old, son of Gaetano, takes over the company.
The first plant in Brazil is built.
The Spanish branch is set up. The Zambon laboratories synthesize N-acetylcysteine.
The headquarters moves to Bresso along with the administrative offices and research laboratory. That same year relations with Japan begin and the company begins working with the EISAI company, which has a license to produce injectable chloramphenicol in Japan.
The new production plant is opened in Cadempino.
Inauguration in Lamone of the Swiss plant for Zambon products.
During this period, the Group begins its international expansion, opening branches in the main European countries and in Central and South America.
Zambon's research identifies a new molecule: fosfomycin trometamol.
From Zambon's research, a new molecular combination is developed: ibuprofen and arginine.
Zambon opens offices in Russia and Hong Kong; a joint venture is agreed in China for the supply of N-acetylcysteine. The American FDA approves production of phosphonomycin trometamol for the US market.
The Chinese plant in Haikou is inaugurated for Zambon products for the domestic market.
New start-up companies developed Zcube, in innovative sectors.
Zambon Group celebrates its Centenary.
The Zambon Museum is opened.
Zambon has a strong “External Manufacturing Management” network, an outsourced virtual production plant that involves more than 80 subcontractors worldwide
Zambon enters in two new therapeutic area: the one of Central Nervous System (CNS) with the molecule Safinamide for the treatment of Parkinson’s disease, as well as Rare Diseases with the acquisition from Philips of Profile Pharma for the treatment of Cystic Fibrosis.
CHMP recommends Approval of XadagoTM (Safinamide) to treat Parkinson's disease in the EU.
The European Commission approved Xadago® for mid to late stage Parkinson's disease patients.
Zambon launches Xadago® (Safinamide) for patients with mid- to late- stage Parkinson's disease in Germany